Other concerns expressed by the advanced breast cancer 4 meeting were regarding the frequency of GnRH agonist administration where despite data from a phase III non-inferiority trial showing no difference between 3-monthly vs. monthly regimens (159), some patients were not fully suppressed with the 3-monthly regimen, and had their menses back. Here, GNRH1 is linked to breast cancer.